Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Farletuzumab Ecteribulin in Solid Tumors
NCT03386942Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Oct 2022
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of farletuzumab ecteribulin in solid tumor, ovarian carcinoma, non-small cell lung cancer (NSCLC) and 3 more, sponsored by Eisai Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events up to 50 months and 7 more. Started Nov 2017; status: completed.
02
Drugs
farletuzumab ecteribulin
03
Conditions
solid tumorovarian carcinomanon-small cell lung cancer (NSCLC)endometrial carcinomafallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT03386942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386942.